BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34331549)

  • 1. Systematic review and meta-analysis of diagnostic performance of CT imaging for assessing resectability of pancreatic ductal adenocarcinoma after neoadjuvant therapy: importance of CT criteria.
    Yang HK; Park MS; Choi M; Shin J; Lee SS; Jeong WK; Hwang SH; Choi SH
    Abdom Radiol (NY); 2021 Nov; 46(11):5201-5217. PubMed ID: 34331549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis.
    Park S; Jang JK; Byun JH; Kim JH; Lee SS; Kim HJ; Hong SB; Park SH
    Eur Radiol; 2021 May; 31(5):3383-3393. PubMed ID: 33123793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
    Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
    Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
    Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
    J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI vs. CT for pancreatic adenocarcinoma vascular invasion: comparative diagnostic test accuracy systematic review and meta-analysis.
    Jajodia A; Wang A; Alabousi M; Wilks C; Kulkarni A; van der Pol CB
    Eur Radiol; 2023 Oct; 33(10):6883-6891. PubMed ID: 37083741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
    Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study.
    Kim HY; Lee YJ; Chang W; Cho J; Park JH; Lee JC; Kim J; Hwang JH; Kim YH
    Eur Radiol; 2022 Jun; 32(6):3799-3807. PubMed ID: 35032213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified National Comprehensive Cancer Network Criteria for Assessing Resectability of Pancreatic Ductal Adenocarcinoma.
    Noda Y; Goshima S; Kawada H; Kawai N; Miyoshi T; Matsuo M; Bae KT
    AJR Am J Roentgenol; 2018 Jun; 210(6):1252-1258. PubMed ID: 29629801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis.
    Kim BR; Kim JH; Ahn SJ; Joo I; Choi SY; Park SJ; Han JK
    Eur Radiol; 2019 Jan; 29(1):362-372. PubMed ID: 29931561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does CT overestimate extra-pancreatic perineural invasion in patients with pancreatic ductal adenocarcinoma following neoadjuvant chemoradiation therapy?
    Noda Y; Pisuchpen N; Parakh A; Srinivas-Rao S; Kinowaki Y; Mino-Kenudson M; Kambadakone AR
    Br J Radiol; 2024 Feb; 97(1155):607-613. PubMed ID: 38305574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
    Schorn S; Demir IE; Reyes CM; Saricaoglu C; Samm N; Schirren R; Tieftrunk E; Hartmann D; Friess H; Ceyhan GO
    Cancer Treat Rev; 2017 Apr; 55():96-106. PubMed ID: 28342938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.
    Allen VB; Gurusamy KS; Takwoingi Y; Kalia A; Davidson BR
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD009323. PubMed ID: 27383694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of Dark-Blood Dual-Energy CT Images for Predicting Vascular Involvement and R0 Resection in Patients With Pancreatic Cancer.
    Si K; Wu H; Yang M; Guo Y; Zhang X; Ding C; Xue J; Han P; Li X
    AJR Am J Roentgenol; 2023 Jun; 220(6):838-848. PubMed ID: 36541594
    [No Abstract]   [Full Text] [Related]  

  • 15. Pancreas CT assessment for pancreatic ductal adenocarcinoma resectability: effect of tube voltage and slice thickness on image quality and diagnostic performance.
    Lee DH; Lee SS; Lee JM; Choi JY; Lee CH; Ha HI; Kang BK; Yu MH; Chang W; Park SJ
    Cancer Imaging; 2023 Dec; 23(1):126. PubMed ID: 38111054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular involvement and resectability of pancreatic ductal adenocarcinoma on contrast-enhanced MRI: comparison with pancreatic protocol CT.
    Noda Y; Kawai N; Kaga T; Ishihara T; Hyodo F; Kato H; Kambadakone AR; Matsuo M
    Abdom Radiol (NY); 2022 Aug; 47(8):2835-2844. PubMed ID: 35760922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma.
    Kim HJ; Park MS; Lee JY; Han K; Chung YE; Choi JY; Kim MJ; Kang CM
    Cancer Res Treat; 2019 Jan; 51(1):24-33. PubMed ID: 29397657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicability of current NCCN Guidelines for pancreatic adenocarcinoma resectability: analysis and pitfalls.
    Garces-Descovich A; Beker K; Jaramillo-Cardoso A; James Moser A; Mortele KJ
    Abdom Radiol (NY); 2018 Feb; 43(2):314-322. PubMed ID: 29392370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
    Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ
    Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
    Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
    Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.